PharmaSens
PharmaSens is a Swiss medical device company developing a portfolio of three tubeless, semi-reusable insulin patch pumps (niia essential, advanced, signature) that integrate insulin delivery with continuous glucose monitoring for people with type 1 and insulin-requiring type 2 diabetes, targeting healthcare providers and patients once regulatory clearance is obtained.
- Company typePrivate
- Founded2006
- HeadquartersReinach, Switzerland
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What PharmaSens does
PharmaSens AG is a privately held Swiss medical device company founded in 2006 and headquartered in Biel/Bienne, Switzerland. The company is developing a portfolio of three insulin patch pumps for people with type 1 diabetes and insulin-requiring type 2 diabetes who currently rely on manual injections but find conventional insulin pumps too complex or too costly. Its product family comprises niia essential (a simplified basal-bolus patch pump), niia advanced (a smartphone-controlled pump with external CGM connectivity), and niia signature (a patented single-patch device integrating continuous glucose monitoring with insulin delivery for automated insulin delivery). All three devices share a common architecture: a small, tubeless, semi-reusable form factor with a 2-year reusable main unit, a disposable 3 ml insulin reservoir for extended wear time, and proprietary needle-insertion technology that combines sensor and cannula insertion in a single step.
The company monetizes via medical device hardware sales of pumps and consumables, targeting healthcare providers, endocrinologists, diabetes educators, and patients through standard medical device distribution channels. As of the available data, the products remain investigational in the United States (the website carries an "Investigational Device Limited by United States law to investigational use" notice), with FDA approval submitted in December 2023 and ISO 13485 certification achieved in November 2023. Distribution is anticipated through healthcare providers and diabetes clinics once regulatory clearance is obtained.
PharmaSens' go-to-market relies on enterprise field sales and partnerships with established players in the diabetes technology ecosystem, including a June 2025 strategic partnership with SiBionics to co-develop the niia signature. The company has strengthened its US commercialization readiness through November 2024 board additions of James Peterson (founder of Asante Solutions and CeQur) and Dr. Robert Gabbay (former Chief Scientific and Medical Officer of the American Diabetes Association). No revenue, funding rounds, or commercial launch dates have been publicly disclosed.
PharmaSens firmographics
Firmographics- Name
- PharmaSens
- Legal name
- PharmaSens AG
- Website
- https://pharmasens.com
- Company type
- Private
- Founded year
- 2006
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- PharmaSens is a Swiss medical device company developing a portfolio of three tubeless, semi-reusable insulin patch pumps (niia essential, advanced, signature) that integrate insulin delivery with continuous glucose monitoring for people with type 1 and insulin-requiring type 2 diabetes, targeting healthcare providers and patients once regulatory clearance is obtained.
- Ownership category
- akta.pro rank
PharmaSens industry classification
Industry- Product category
- Diabetes Management Devices
- NAICS
- Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)
- SIC
- Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)
- akta.pro primary industry
- Patch Pumps & Wearable Insulin Delivery (HLAHAHAC)
- akta.pro secondary industry
- Automated Insulin Delivery (AID) / Closed-Loop Systems (HLAHAHAF)
Keywords
Where PharmaSens is headquartered
LocationHeadquarters
- HQ city
- Reinach
- HQ country
- Switzerland
- HQ region
- Europe
Offices1 record
Markets served
PharmaSens business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
Revenue model
- Insulin patch pump hardware sales: PharmaSens generates revenue through the sale of its niia insulin patch pump portfolio, including niia essential, niia advanced, and niia signature devices. The semi-reusable design creates a consumables model with reusable hardware components and disposable insulin reservoirs.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels4 records
PharmaSens product offering
Product offeringCore offering
PharmaSens develops and manufactures a portfolio of three insulin patch pumps (niia essential, niia advanced, and niia signature) for diabetes management. All devices are small, tubeless, semi-reusable patch pumps with a 3 ml insulin reservoir and a 2-year reusable main unit. The niia advanced and niia signature incorporate automated insulin delivery (AID) algorithms, with the niia signature combining insulin delivery and continuous glucose monitoring in a single patented patch device.
Product overview
PharmaSens is developing a portfolio of three insulin patch pumps based on shared technology: niia essential (a standalone basal-bolus pump), niia advanced (a smartphone-controlled pump with external CGM connectivity), and niia signature (an integrated pump-CGM combination device). All three devices are small, tubeless, semi-reusable patch pumps with a 3 ml insulin reservoir allowing extended wear time, a reusable main unit with a 2-year lifetime, and proprietary needle insertion technology combining sensor and needle in one step. The portfolio progresses from simplicity to advanced automation, with niia advanced and niia signature incorporating automated insulin delivery (AID) algorithms.
Differentiator
Problem solved
Functional benefit
Brands
- niia essential: Basal-bolus insulin pump without CGM integration. Reduced complexity for ease of use.
- niia advanced
- niia signature
Products and services
- niia essential Basal-bolus insulin patch pump with reduced complexity for ease of use, combining the simplicity of a pen with the glucose control of a pump. Features tubeless design, smartphone control capability, and semi-reusable architecture, intended for people with diabetes requiring insulin therapy.
- niia advanced Smartphone-controlled insulin patch pump with expanded user options, connectable to external continuous glucose sensors (CGM) for enhanced diabetes management. Incorporates automated insulin delivery (AID) algorithm capabilities.
- niia signature Combined insulin patch pump and continuous glucose monitoring (CGM) system in one device. Patented technology enables simultaneous glucose measurement and insulin delivery from a single patch, representing the most advanced offering in the portfolio with full automated insulin delivery capability.
Quantifiable outcome
- First-in-human clinical study published in Journal of Diabetes Science and Technology demonstrates feasibility of integrated insulin delivery and glucose monitoring in a single wearable device
Companies that use PharmaSens
Customer profileSegments2 records
PharmaSens technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability2 records
Feature5 records
PharmaSens partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- SiBionicsflagshipPharmaSens and SiBionics entered a strategic partnership in June 2025 to co-develop niia signature, a next-generation wearable device that combines insulin delivery with real-time glucose sensing. This collaboration integrates SiBionics' CGM sensor technology with PharmaSens' insulin patch pump to create an all-in-one device that simplifies diabetes management.
Scale indicators6 records
Recent moves6 records
Expansion highlights5 records
PharmaSens competitors and assessment
Company assessmentBroad incumbents
- Roche Diabetes Care:
- Dexcom: Leading CGM manufacturer (G7) integrated into most major AID systems including Insulet, Tandem, and Beta Bionics. Competes indirectly with PharmaSens' integrated niia signature by being the CGM that third-party pumps pair with.
- Abbott Diabetes Care: Makes FreeStyle Libre CGM sensors, the largest installed base of CGMs globally and increasingly integrating with pump partners. Broad incumbent whose Libre sensors are the alternative to SiBionics CGM inside the niia signature.
- Tandem Diabetes Care: Makes the t:slim X2 insulin pump with Control-IQ AID algorithm and recently acquired Sigi patch pump assets. Direct overlap with PharmaSens in the AID and emerging patch pump categories.
- Medtronic Diabetes: MiniMed 780G AID system and Guardian CGM - the incumbent market leader in insulin pump therapy and CGM. Competes across the same patient population and provider channels as PharmaSens with substantially greater scale and distribution.
Emerging players
- Diabeloop: European AID algorithm company whose DBLG1 system integrates with multiple pump hardware platforms. Partnered with PharmaSens via Scientific Advisory Board (Prof. Benhamou is CMO at Diabeloop); comparable AID strategy and European focus.
- Beta Bionics: Maker of the iLet bionic pancreas AID system, approved by FDA in 2023. Emerging peer in the automated insulin delivery category with similar algorithm-driven approach and focus on simplifying pump therapy for broad adoption.
Direct peers
- Insulet Corporation: Maker of the Omnipod tubeless patch pump and Omnipod 5 AID system. Most direct competitor to PharmaSens' niia portfolio, with the same target market (people with insulin-requiring diabetes) and overlapping AID + patch pump architecture.
- Ypsomed: Swiss-headquartered manufacturer of the mylife YpsoPump and developer of the YpsoPump with CGM-integrated AID. Most direct European peer, sharing PharmaSens' Swiss medtech heritage and insulin patch pump focus.
- CeQur: Developer of the PaQ wearable insulin delivery device for type 2 diabetes. Founded by James Peterson, who is now on PharmaSens' board - making it a tightly connected peer in the simplified insulin patch delivery category.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat4 records
Key risks6 records
Key highlights7 records
Customer concentration
PharmaSens social profiles
Digital presencePharmaSens compliance and trust
Trust signalCompliance1 record
PharmaSens financial estimates
Financial estimateRevenue estimate
Valuation estimate
PharmaSens leadership team
Management profileNumber of profiles
PharmaSens funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
PharmaSens M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about PharmaSens
What does PharmaSens do?
PharmaSens develops and manufactures a portfolio of three insulin patch pumps (niia essential, niia advanced, and niia signature) for diabetes management. All devices are small, tubeless, semi-reusable patch pumps with a 3 ml insulin reservoir and a 2-year reusable main unit. The niia advanced and niia signature incorporate automated insulin delivery (AID) algorithms, with the niia signature combining insulin delivery and continuous glucose monitoring in a single patented patch device.
Is PharmaSens a public or private company?
PharmaSens is a private company. It is classified as unknown and is currently operating.
When was PharmaSens founded?
PharmaSens was founded in 2006. It employs 11 to 50 people.
Where is PharmaSens based?
PharmaSens is headquartered in Reinach, Switzerland, in the Europe region.
How does PharmaSens make money?
One revenue line is on record: insulin patch pump hardware sales.
Who are PharmaSens's main competitors?
Broad incumbents on record are Roche Diabetes Care, Dexcom, Abbott Diabetes Care, Tandem Diabetes Care and Medtronic Diabetes. Emerging players are Diabeloop and Beta Bionics. Direct peers are Insulet Corporation, Ypsomed and CeQur.
Does PharmaSens have an API?
No public API is recorded for PharmaSens.
What industry is PharmaSens in?
PharmaSens's product category is Diabetes Management Devices. Its primary akta.pro industry code is HLAHAHAC, Patch Pumps & Wearable Insulin Delivery, with a secondary code of HLAHAHAF, Automated Insulin Delivery (AID) / Closed-Loop Systems. Its NAICS code is 339112 and its SIC code is 3841.